Larkin JMG, et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma. Abstract LBA68_PR. ESMO Congress 2019, 28 sept, Barcelona, Spanje.
177Lu-PSMA-617 beter dan cabazitaxel in fase II-studie
apr 2021 | Uro-oncologie